COMPANY PROFILE

Resistell

Explore full profile

Offers an alternative to culture-based antibiogram, the gold standard in antibiotic susceptibility testing (AST)

Muttenz, SwitzerlandFounded 2017Biotech & Life Sciences

Valuation $25–50M Last recorded · 2022

Revenue <$1M Latest reported FY

Headcount <100 Current team size

Total funding $10–50M Disclosed equity funding

Unlock exact values

About Resistell

Developer of an antibiotic susceptibility device designed to offer an alternative to a culture-based antibiogram. The company's device is based on the detection of movement caused by living bacterial cells to determine bacterial resistance to antibiotics, enabling patients to have proper antibiotics on time. Keywords: Pharmaceuticals and Biotechnology, Healthcare Devices / Services / Supplies, Antibiotic Resistance, Antibiotic Resistance Analysis, Antibiotic Susceptibility, Antibiotic Susceptibility Test, Antimicrobial Resistance, Antimicrobial Resistance Monitoring.

Source: Dealroom company data

At a glance

Status: Operational
Founded: 2017
Headquarters: Muttenz, Switzerland
Employees: 14
Open positions: None listed
Dealroom signal: 61.6/100
Industry: Health
Sub-industry: BioTechnology, Medical Devices, Health Platform
Sector: Biotech & Life Sciences, Biotechnology, Pathology, Health Diagnostics, Spinout, EIC, Clinical Decision Support
Technology: Hardware, Deep Tech
Business model: Manufacturing
Client focus: b2b
Links: Website LinkedIn X

Knowledge graph

News, research, reports and resources connected to this company by Dealroom

Funding history

7 recorded events

Company financing events and reported valuations.

Deal type	Date	Amount	Valuation	Investors	Source
SERIES B✓Equity / VC	Dec 2022	$9.4M	$38M	Launchpad · EIC Fund · ZKB - Zürcher Kantonalbank · TRUMPF Venture	↗
EARLY VC✓Equity / VC	Mar 2020	$0	—	EIC Fund	—

Showing the latest 2 of 7 recorded eventsBook a demo for the full funding history →

Financials

Revenue over time

Revenue, earnings and other financial measures where available. Years marked “E” are estimates.

Year	Revenue	Growth
2026
2025
2024
2023
2022
2021
2020		—

Company filings, research estimates and Dealroom dataBook a demo for the full financial model →

Growth signals

Resistell website traffic

Latest recorded traffic for Resistell is 340 monthly website visits, down 52.1% over the last three months. Resistell's team declined 30% over the past year.

Latest monthly visits340 3-month web change-52.1% 1-year team growth-30%

Monthly website visitsFeb 2018–Jun 2026

Explore monthly traffic historyTrack growth over time and compare with peersBook a demo

Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Company	Headquarters	Status	Employees	Total funding	Valuation
NDNovus DiagnosticsDeveloping ground-breaking diagnostics technologies that provide rapid answers right at the patient’s bedside	Dublin, Ireland	Operational	11	$15M	$20M
INInBiomeRadically accelerating human healthcare	Amsterdam, Netherlands	Operational
OPOphiomicsOphiomics develops bioinformatics/genomics-based diagnostic products and services for liver cancer diagnosis, prognosis and follow-up.	Lisbon, Portugal	Operational
GEGenomtecInnovative diagnostic device, based on the amplification and detection of specific DNA and RNA fragments	Wroclaw, Poland	Operational
PIPicturaBioBuilding instant pathogen tests using super-resolution microscopy and machine learning	Oxford, United Kingdom	Operational
ODOsler DiagnosticsA ground-breaking handheld diagnostic for testing a vast range of biomarkers	Oxford, United Kingdom	Operational
ATADmit TherapeuticsEpigenetic blood test for early Alzheimer's prognosis	Esplugues de Llobregat, Spain	Operational
EVEverZomA key asset to the future health of an ageing population	Paris, France	Operational